GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (SHSE:688185) » Definitions » EV-to-FCF

CanSino Biologics (SHSE:688185) EV-to-FCF : -14.97 (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CanSino Biologics EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CanSino Biologics's Enterprise Value is ¥9,926.0 Mil. CanSino Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-663.1 Mil. Therefore, CanSino Biologics's EV-to-FCF for today is -14.97.

The historical rank and industry rank for CanSino Biologics's EV-to-FCF or its related term are showing as below:

SHSE:688185' s EV-to-FCF Range Over the Past 10 Years
Min: -42.27   Med: -4.75   Max: 160.07
Current: -16.18

During the past 8 years, the highest EV-to-FCF of CanSino Biologics was 160.07. The lowest was -42.27. And the median was -4.75.

SHSE:688185's EV-to-FCF is ranked worse than
100% of 550 companies
in the Drug Manufacturers industry
Industry Median: 25.795 vs SHSE:688185: -16.18

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), CanSino Biologics's stock price is ¥64.39. CanSino Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ¥-3.513. Therefore, CanSino Biologics's PE Ratio (TTM) for today is At Loss.


CanSino Biologics EV-to-FCF Historical Data

The historical data trend for CanSino Biologics's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics EV-to-FCF Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial -39.03 -42.98 37.66 -4.06 -2.57

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 126.25 -34.33 -2.57 -2.71 -4.73

Competitive Comparison of CanSino Biologics's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CanSino Biologics's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's EV-to-FCF falls into.



CanSino Biologics EV-to-FCF Calculation

CanSino Biologics's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9926.035/-663.082
=-14.97

CanSino Biologics's current Enterprise Value is ¥9,926.0 Mil.
CanSino Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-663.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CanSino Biologics  (SHSE:688185) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CanSino Biologics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=64.39/-3.513
=At Loss

CanSino Biologics's share price for today is ¥64.39.
CanSino Biologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-3.513.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CanSino Biologics EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

CanSino Biologics Headlines

No Headlines